vTv Therapeutics completes enrollment in Phase 3 type 1 diabetes trial

October 5, 2026 8:00 AM

vTv Therapeutics Inc. (Nasdaq: VTVT) announced the completion of enrollment in its Phase 3 CATT1 study evaluating cadisegliatin as an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found